The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Limited advances in second-line treatments for metastatic ESCC
David Tougeron, MD, PhD, Poitiers University Hospital, Poitiers, discusses the current treatment landscape for metastatic esophageal squamous cell carcinoma (mESCC). Immune checkpoint inhibitors such as nivolumab and pembrolizumab are used in combination with 5-fluorouracil (5-FU) and cisplatin as a first-line therapy. However, there are no new targeted options available, and the efficacy of second-line treatments remains poor, with no promising new treatments on the horizon. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
